Company news

CervoMed Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

CervoMed Provides Update on Neflamapimod DLB Program as Part of Presentation at the 8th International Lewy Body Dementia Conference

January 30, 2025

CervoMed to Present at the 8th International Lewy Body Dementia Conference

January 28, 2025

CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 11, 2024

CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies

December 9, 2024

CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia

November 26, 2024

CervoMed Announces Key Senior Leadership Appointments

November 12, 2024

CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

November 11, 2024

CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup

November 7, 2024

CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)

November 3, 2024

CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference

October 28, 2024

CervoMed Announces Last Patient Last Visit in Phase 2b RewinD-LB Trial of Neflamapimod for the Treatment of Early-Stage Dementia with Lewy Bodies (DLB)

October 14, 2024

CervoMed Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

August 11, 2024

CervoMed Announces Presentation at AAIC 2024 on Plasma Biomarker Data That Are Consistent with Neflamapimod Impacting the Underlying Disease Process in Patients with Dementia with Lewy bodies (DLB)

July 28, 2024

CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024

July 10, 2024

CervoMed Announces Addition to Russell 2000® and Russell 3000® Indexes

June 23, 2024

CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies

June 10, 2024

CervoMed to Appoint William Elder as Chief Financial Officer

May 19, 2024

CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates

May 14, 2024

CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

March 31, 2024

CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors

March 27, 2024

CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024

March 4, 2024

CervoMed appoints drug development veteran Dr. Joshua Boger as Chairman of the Board

February 19, 2024

CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board

February 6, 2024

CervoMed Reports Third Quarter 2023 Financial Results and Business Highlights

November 12, 2023

CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Learnings from Phase 2a Which Optimized the Design of the Phase 2b Clinical Study of Neflamapimod in Dementia with Lewy Bodies

October 24, 2023

CervoMed Announces Publications in Major Peer-Reviewed Journals That Inform on Potential of Neflamapimod as a Disease-Modifying Therapy for the Major Dementias

October 23, 2023

CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Phase 2b Neflamapimod Program for the Treatment of Patients with Dementia with Lewy Bodies

October 17, 2023

← Newer news releases

Decks

The 5 newest of 16 decks. Every deck is listed under its year.